Organized by the Spanish Proteomics Society (SEProt)
Thursday, September 29th (17h00-18h30)
Room B

Following the sequencing of the human genome, one of the challenges of this century is depicting the human proteome, much more diverse and dynamic. Indeed, the Human Proteome Project was launched to map the protein-based molecular architecture of the human body and help to elucidate biological and molecular functions of proteins and improve diagnosis and treatment of diseases. The latter is the basis of Clinical Proteomics, which aims to take advantage of modern proteomics technology to identify novel biomarkers and drug targets. This session will be of special interest to researchers and pharmaceutical companies devoted to biomarker and drug target discovery. There will be four speakers, including the chairman, with expertise in clinical/translational proteomics. They will show some recent advances in the field, both technological and related to applications, with special emphasis in brain injury, liver and cardiovascular disease.

Organized by:

Moderator & Speaker:

  • Ángel García:  President, SEPROT / Head of the Platelet Proteomics Group at the Center for Research in Molecular Medicine and Chronic Diseases - CIMUS, UNIVERSITY OF SANTIAGO DE COMPOSTELA (Spain).  “Proteomics applied to the search of anti-platelet drug targets in acute myocardial infarction”. 


  • Fernando J. Corrales: General Coordinator of ProteoRed - Carlos III Networked Proteomics Platform / Director of the Proteomics, Genomics and Bioinformatics Platform of the Center for Applied Medical Research-CIMA, UNIVERSITY OF NAVARRA (Spain). “Proteomics applied to liver disease: biomarkers and validation methods”. 
  • Félix Elortza:  Proteomics Platform Manager. CIC bioGUNE (Spain). “New approaches for clinical proteomics: molecular histology by MALDI-TOF Imaging mass spectrometry and peptidomics on biofluids”. 
  • Jean-Charles Sanchez:  Head of the Translational Biomarker Group, Human Protein Sciences Department, CENTRE MEDICAL UNIVERSITAIRE OF GENEVA (Switzerland). “Brain injury biomarker discovery and their translation to clinical settings”. 

  • Discussion & conclussions